2021
DOI: 10.3390/life11111168
|View full text |Cite
|
Sign up to set email alerts
|

Abstract: The burden of neurodegenerative diseases in the central nervous system (CNS) is increasing globally. There are various risk factors for the development and progression of CNS diseases, such as inflammatory responses and metabolic derangements. Thus, curing CNS diseases requires the modulation of damaging signaling pathways through a multitude of mechanisms. Peroxisome proliferator-activated receptors (PPARs) are a family of nuclear hormone receptors (PPARα, PPARβ/δ, and PPARγ), and they work as master sensors … Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
2

Citation Types

0
4
0

Year Published

2022
2022
2023
2023

Publication Types

Select...
5

Relationship

1
4

Authors

Journals

citations
Cited by 8 publications
(4 citation statements)
references
References 111 publications
(180 reference statements)
0
4
0
Order By: Relevance
“…Specifically, the PPAR-alpha phosphoprotein has been linked to immune and inflammation responses, autophagy in human microglia, oxidative phosphorylation, regulation of the oxidative metabolism of skeletal muscle and energy homeostasis [ 61 , 85 , 87 ]. PPAR-alpha has been proposed as a putative novel therapeutic target in various diseases, including ALS, slowing the progression of the disease [ 107 , 108 ]. Specifically, an in vivo ALS study demonstrated that the activation of PPAR-alpha results in neuroprotection, neuroinflammation reduction, and neurodegeneration blocking [ 108 ].…”
Section: Discussionmentioning
confidence: 99%
“…Specifically, the PPAR-alpha phosphoprotein has been linked to immune and inflammation responses, autophagy in human microglia, oxidative phosphorylation, regulation of the oxidative metabolism of skeletal muscle and energy homeostasis [ 61 , 85 , 87 ]. PPAR-alpha has been proposed as a putative novel therapeutic target in various diseases, including ALS, slowing the progression of the disease [ 107 , 108 ]. Specifically, an in vivo ALS study demonstrated that the activation of PPAR-alpha results in neuroprotection, neuroinflammation reduction, and neurodegeneration blocking [ 108 ].…”
Section: Discussionmentioning
confidence: 99%
“…PPARα regulates several important processes in the neural circuits, including neural cell proliferation and differentiation, neurotransmission, and synaptic plasticity. It has previously been investigated as a novel therapeutic target for neurodegenerative and neuropsychiatric diseases ( Fidaleo et al, 2014 ; D’Angelo et al, 2018 ; Lee et al, 2021 ). However, bilirubin receptors in the CNS remain unknown and it remains to be investigated whether their downstream signaling pathways are involved in bilirubin-induced neurological changes.…”
Section: Discussionmentioning
confidence: 99%
“…15,16 Over the past decades, a positive point of view on PPARα modulation-based therapy has been stacked in the central nervous system diseases in terms of the protective and preventive effects. 17 Along with this, pemafibrate was also on the rise as a promising preventive drug in retinal ischemia. 18 In several rodent models, pemafibrate showed preventive effects on ocular neovascularization, dysfunction of retinal electrical responses, loss of retinal ganglion cells, and retinal inflammation.…”
Section: Introductionmentioning
confidence: 98%
“…Pemafibrate is a selective peroxisome proliferator‐activated receptor α (PPARα) modulator, which was developed and marketed by Kowa Pharmaceuticals as a clinically effective treatment for metabolic diseases, including dyslipidemia 15,16 . Over the past decades, a positive point of view on PPARα modulation‐based therapy has been stacked in the central nervous system diseases in terms of the protective and preventive effects 17 . Along with this, pemafibrate was also on the rise as a promising preventive drug in retinal ischemia 18 .…”
Section: Introductionmentioning
confidence: 99%